



UNITÉ DE PHARMACOLOGIE CLINIQUE ET PHARMACOVIGILANCE

Global Health EDCTP3 Joint Undertaking

56 – 60 Avenue de la Toison d'Or

1060 Brussels

Belgium

26/08/2025

Letter of endorsement

Dear Sir/Madam,

On behalf of the **UNIVERSITE DE KINSHASA/UNITE DE PHARMACOLOGIE CLINIQUE ET PHARMACOVIGILANCE (UPC-PV)**, Avenue de l'Université N°1, Kinshasa/Lemba, Democratic Republic of Congo and in accordance with Council Regulation (EU) No 2085/2021 of 19th November 2021 establishing the joint undertakings under Horizon Europe and specifically Article 9 therein, I hereby submit an application to become a contributing partner to the Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3 JU).

UPC-PV is a research center created in 2009 at the University of Kinshasa and dedicated to clinical research and therapeutic evaluations of medicines, as well as pharmacovigilance, with a focus on infectious and neglected tropical diseases. UPC-PV is a member of CANTAM, funded by EDCTP, and the focal point for antimalarial resistance within the CATCR project.

The activities undertaken by UPC-PV as part of its mission and objectives contribute to the goals of the EDCTP3 joint undertaking for global health. UPC-PV contributes to reducing morbidity and mortality in the DRC by ensuring that everyone has access to effective and innovative diagnostic tools and safe and effective drug treatments. The DRC's pharmaceutical regulatory authority uses UPC-PV to implement pharmacovigilance activities in the country. We have developed collaborations with national and international partners in clinical trials for the development of innovative medicines and vaccines, particularly against diseases such as Ebola, monkey pox, trypanosomiasis, etc. As an academic institution, UPC-PV is committed to training and mentoring the next generation of African scientists in order to produce a critical mass of researchers in Central Africa who will generate the scientific evidence needed for decisions and policies to combat diseases, especially infectious diseases.

UPC-PV will actively contribute to the PRESERVE project by participating in work packages 2, 5 and 7. As part of Work Package 2 (Capacity Building), UPC-PV, as a clinical pharmacology unit, has proven experience in clinical research during the COVID pandemic and epidemics of Ebola, monkeypox and the introduction of new vaccines; it will be able to share this experience during the training of trainers. As part of Work Package 5 (Study Preparation, Ethics Approval and Participant Recruitment for strengthening TB Diagnostics), UPC-PV is collaborating with the Ministry of Health's specialized programs in studies involving the recruitment and sampling of tuberculosis patients. It will thus facilitate the achievement of the planned sample sizes. For Work Package 7 (Arboviral Disease Surveillance and Vector Control in Central Africa: Integrating Genomic Epidemiology, Molecular Diagnostics, and AI-Driven Approaches), in DRC we are already working

**REPUBLIQUE DEMOCRATIQUE DU CONGO
MINISTERE DE L'ENSEIGNEMENT SUPERIEUR ET UNIVERSITAIRE
UNIVERSITE DE KINSHASA**



UNITÉ DE PHARMACOLOGIE CLINIQUE ET PHARMACOVIGILANCE

in certain regions where there are arbovirus outbreaks. UPC-PV will provide its expertise and resources to help improve detection and integrate molecular tools into the surveillance of dengue (DENV), chikungunya (CHIKV), Zika virus (ZIKV), yellow fever (YFV) and Rift Valley fever virus (RVFV) surveillance in Central Africa.

We estimate the total value of this contribution covering facility use, equipment time, personnel effort, and training platform access; to be EUR 23,600 EUR.

We confirm the following:

1. We will comply with the Horizon Europe Regulation (EU) No 2021/695; Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe; the Model Grant Agreement for Horizon Europe and applicable Global Health EDCTP3 JU rules, including the relevant work programmes and in particular the call conditions therein.
2. We will keep all information received in the context of our involvement as contributing partner to the Global Health EDCTP3 JU confidential. This confidentiality obligation applies in particular but is not limited to the areas of Global Health EDCTP3 JU call topic preparation and publication, proposal submission and evaluation, and consortium formation. We further understand that this obligation strictly prohibits the release of confidential information to any legal entities save where specifically authorised by Global Health EDCTP3 JU. Internal dissemination of information within our organisation will be done on the basis of the “need-to-know” principle.
3. We are confident of our ability to fulfil the above commitments and further confirm our understanding that the Global Health EDCTP3 JU will allocate resources to the above topic based on these commitments.
4. The value of our contribution will be based on costs calculated in accordance with Article 6 of the Horizon Europe Model Grant Agreement.
5. We accept that additional modalities regarding the provision of our contribution may be defined in subsequent agreements or documents, such as a funding agreement and topic text.

Yours faithfully,

26/08/2025

Gauthier MESIA KAHUNU

Executive Secretary